Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Terminated 5Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Lymphoma 2Neoplasms, Plasma Cell 1Neoplasms 1Leukemia 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × plitidepsin × Clear all
NCT01102426 2020-11-10

ADMYRE

PharmaMar

Phase 3 Completed
255 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT02100657 2020-10-12

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

PharmaMar

Phase 1 Completed
39 enrolled 30 charts
Plasma cell

Multiple Myeloma

NCT00884286 2018-04-25

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

PharmaMar

Phase 2 Completed
67 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT00788099 2011-06-07

Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

PharmaMar

Phase 1 Completed
45 enrolled
Lymphoid

Lymphoma, Neoplasms

NCT00229203 2009-12-24

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

PharmaMar

Phase 2 Completed
51 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡